Key result
Left atrial appendage closure with the WATCHMAN device is a reasonable and effective alternative for stroke prevention in patients with non-valvular atrial fibrillation who are contraindicated to systemic oral anticoagulants.
Why the study?
Warfarin reduces systemic embolization in AF but is challenging due to a limited therapeutic window and bleeding risks, necessitating alternative stroke-prevention therapies for ineligible patients.
Does left atrial appendage closure with the WATCHMAN device prevent stroke in non-valvular AF patients ineligible for warfarin?
Does left atrial appendage closure with the WATCHMAN device prevent stroke in non-valvular AF patients ineligible for warfarin?
The WATCHMAN device provides a safe and effective alternative for stroke prevention in patients with non-valvular atrial fibrillation who are contraindicated for long-term oral anticoagulation.
Supports LAA closure consideration in contraindicated NVAF; leaves open randomized confirmation of benefit.
Aim:The aim of this study was to evaluate the safety and effectiveness of LAA closure in nonvalvular AF patients who were ineligible for warfarin medication.Atrial fibrillation (AF) is the most frequently encountered cardiac arrhythmia.It is the main cardiac cause to stroke.Despite the possibility that atrial fibrillation is a lifelong condition, a number of therapies and risk-reduction measures have been developed.Warfarin has been shown to have the ability to decrease systemic Embolization in AF patients, but its usage is challenging due to its limited therapeutic window and more side effects (such as a higher probability of bleeding), particularly in older patients.As a result, these individuals need other forms of therapy in order to lower their risk of stroke.In patients with non-valvular AF, the left atrial appendage is the primary source of thrombus development.The permanent implant known as the WATCHMAN Device is intended to block the left atrial appendage in the heart in an effort to lower the risk of stroke. Conclusion:LAA closure with the watchman device can be successfully operated without a warfarin transition and is a reasonable alternative for the patients at high risk for stroke contraindicated to systemic oral anticoagulants.
No takes yet. Share an insight, caveat, or question.
Sanober et al. (2023) conducted a review in Non-valvular atrial fibrillation. WATCHMAN Device vs. Warfarin or other oral anticoagulants was evaluated. Left atrial appendage closure with the WATCHMAN device is a reasonable and effective alternative for stroke prevention in patients with non-valvular atrial fibrillation who are contraindicated to systemic oral anticoagulants.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: